This week’s clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics’ DT120 becomes the first lysergide therapy to succeed in a Phase 3 major depressive disorder trial; Pfizer’s sigvotatug vedotin fails to beat chemotherapy in second-line lung cancer; and Cynata Therapeutics is left reviewing the future of its entire Cymerus platform after CYP-004 misses both co-primary endpoints in the Phase 3 SCUlpTOR knee osteoarthritis trial.
The Definium result is a genuinely historic one: a Phase 3 success for a lysergide-based therapy in major depressive disorder marks a watershed moment in the long effort to bring psychedelic compounds into the regulated pharmaceutical mainstream, underscoring that rigorous trial design can overcome longstanding scepticism about the class. Against that backdrop, the ADC failure in lung cancer and the platform setback in stem cell therapy are reminders of how unforgiving late-stage development remains, even for mechanistically compelling approaches.
Definium Therapeutics’ DT120 Becomes First Lysergide Therapy to Succeed in a Phase 3 Major Depressive Disorder Trial
Definium Therapeutics announced on 22 June 2026 positive topline results from the Phase 3 Emerge study evaluating a single 100 microgram dose of DT120 (lysergide) orally disintegrating tablet (ODT) versus placebo in adults with major depressive disorder (MDD). The study met its primary endpoint and all key secondary efficacy endpoints.
The primary endpoint, change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 6, showed an 8.1-point placebo-adjusted improvement in the DT120 arm (p<0.0001). This effect was maintained at week 12, a key secondary endpoint, with a 7.3-point placebo-adjusted improvement (p<0.0001). DT120 ODT was generally well tolerated, with no serious adverse events and no suicidality signal reported across the study.
Emerge was a Phase 3, multicentre, randomised, double-blind, placebo-controlled study enrolling 149 adults aged 18 to 74 years with a DSM-5-confirmed diagnosis of MDD, a MADRS total score of at least 26, and a Clinical Global Impression-Severity (CGI-S) score of at least 4 at screening, across 20 sites. The study comprised a 12-week double-blind phase (Part A) followed by a 40-week open-label extension (Part B). To address concerns about functional unblinding inherent to psychedelic compounds, the development programme incorporates a 50 microgram placebo-like confound arm in the ongoing second Phase 3 study, Ascend, consistent with FDA guidance and aligned with the approach taken in Definium’s earlier Phase 2b study in generalised anxiety disorder.
DT120 ODT is an advanced formulation of lysergide (LSD), an ergoline derivative belonging to the class of serotonergic psychedelics, which acts as a partial agonist at 5-HT2A receptors among other targets. It uses Catalent’s Zydis ODT fast-dissolve technology, designed to improve bioavailability and reduce gastrointestinal side effects. MDD is the second most common mental health disorder in the United States, affecting more than 21 million adults each year, and carries a $326 billion annual economic burden driven by healthcare costs and lost productivity. Fewer than one third of patients reach remission with first-line pharmacotherapy, and current treatments typically require weeks to months to produce clinical benefit.
Definium is developing DT120 ODT across multiple psychiatric indications, including MDD, generalised anxiety disorder (GAD), and post-traumatic stress disorder (PTSD). The company plans to advance towards FDA submission, with a second Phase 3 trial, Ascend, already under way. A second positive Phase 3 result would ordinarily be required to support full approval. Emerge represents the first Phase 3 success for any lysergide-based therapeutic in a major psychiatric indication.
Pfizer’s Sigvotatug Vedotin Fails to Improve Overall Survival in Phase 3 NSCLC Trial
Pfizer announced on 22 June 2026 topline results from the Phase 3 SigVie-002 study (NCT06012435) evaluating sigvotatug vedotin, an investigational integrin beta-6 (IB6) directed antibody-drug conjugate (ADC), in adults with previously treated locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC). In the overall study population, sigvotatug vedotin did not demonstrate a statistically significant improvement in the primary endpoint of overall survival (OS) compared with docetaxel.
The Phase 3, open-label, randomised, global SigVie-002 study enrolled 703 patients with locally advanced, unresectable, or metastatic non-squamous NSCLC who had received one or more prior lines of systemic therapy. Participants were randomised to receive sigvotatug vedotin administered intravenously on Days 1 and 15 of each 28-day cycle, or docetaxel administered intravenously on Day 1 of each 21-day cycle. The safety profile of sigvotatug vedotin was manageable and consistent with prior studies.
Pfizer noted an encouraging signal in the approximately two thirds of patients who had received only one prior line of therapy: this subgroup showed a stronger trend towards improved OS and progression-free survival (PFS) with sigvotatug vedotin over docetaxel. Exploratory biomarker analysis found no evidence that IB6 expression level correlated with response magnitude, despite IB6 being expressed on approximately 90% of NSCLC tumours, which complicates the identification of a predictive biomarker for this agent.
Sigvotatug vedotin was acquired through Pfizer’s $43 billion purchase of Seagen in 2023 and represents a key asset in the company’s ADC expansion strategy. Pfizer is continuing to evaluate the drug in an ongoing Phase 3 study in combination with pembrolizumab in first-line NSCLC with PD-L1 tumour proportion score of 50% or higher, as well as in early-stage lung cancers in combination with PF-4404, a novel bispecific antibody targeting PD-1 and VEGF. The biomarker finding complicates the picture further: IB6 is expressed on approximately 90% of NSCLC tumours, yet expression level appears to have no bearing on response, leaving the field without a viable patient selection strategy for this agent in its current form. The SigVie-002 failure is a setback for the ADC field more broadly, reflecting a recurring challenge: high target expression does not reliably translate into clinical benefit, and docetaxel remains a more competitive second-line benchmark than many trials anticipate. Whether the combination approach in first-line patients with high PD-L1 expression can rescue the programme remains an open question, but the subgroup signal from SigVie-002 at least provides a scientific rationale for continuing.
Cynata Therapeutics’ CYP-004 Misses Both Co-Primary Endpoints in Phase 3 Knee Osteoarthritis Trial, Placing Cymerus Platform Under Review
*This story incorporates the Phase 2 CYP-001 graft-versus-host disease result, announced on 17 June 2026, one day before the coverage window, given its direct relevance to understanding the Phase 3 SCUlpTOR outcome reported on 19 June and the subsequent platform review.*
Cynata Therapeutics announced on 19 June 2026 that the Phase 3 SCUlpTOR trial evaluating CYP-004, its Cymerus-derived iPSC-derived mesenchymal stromal cell (MSC) therapy administered as a single intra-articular injection, had missed both co-primary endpoints in patients with medial tibiofemoral knee osteoarthritis. The trial was a randomised, placebo-controlled study led by the University of Sydney and funded through an Australian Government NHMRC project grant, enrolling 321 participants over a two-year follow-up period.
The first co-primary endpoint was the proportion of patients achieving patient-acceptable symptom state (PASS) for knee pain at 24 months: 51.7% of CYP-004-treated patients met this threshold compared with 48.1% in the saline placebo arm (p=0.5907), a non-significant difference. The second co-primary endpoint, central medial femorotibial cartilage thickness change from baseline to 24 months as assessed by MRI, showed a loss of 0.27mm in the active arm versus 0.21mm in the placebo arm, with no statistical separation and a directional trend unfavourable to the drug. There were no safety concerns identified in either arm.
The failure has been attributed in part to an unexpectedly high placebo response rate: the trial was designed assuming approximately 35% of placebo patients would reach the pain threshold, but nearly half did. Intra-articular saline injection is one of the most potent placebos in musculoskeletal medicine, generating measurable pain reduction that can persist for months, and the SCUlpTOR design was insufficient to fully account for this effect.
The result followed closely behind the Phase 2 CYP-001 failure in high-risk acute graft-versus-host disease (aGvHD), announced on 17 June, in which all primary and key secondary endpoints failed to show meaningful benefit compared with steroid plus placebo across 65 enrolled patients, prompting Cynata to terminate the trial early. Together, these represent back-to-back failures across two different indications using the same underlying Cymerus iPSC-derived MSC technology. Cynata has announced a formal review of options for further development of the Cymerus platform and has not yet indicated whether any assets will be advanced.
Looking Ahead
This week’s clinical trial results 26 June 2026 span the full arc of the pipeline, from landmark success to sobering failure. Definium’s Emerge result is genuinely historic: a rigorous Phase 3 trial demonstrating that a single low dose of a lysergide compound can produce rapid, durable antidepressant effects sets a new precedent for the field and moves the psychedelic medicine programme decisively beyond proof of concept. The Pfizer ADC failure in NSCLC underlines the difficulty of beating a chemotherapy benchmark in a heavily pretreated population, while the subgroup signal in second-line patients suggests that refined patient selection and combination strategies may yet yield value from this programme. And Cynata’s double platform failure is a rare moment of honesty from the stem cell field: iPSC-derived MSC therapies have compelling scientific rationale, but translating that into controlled Phase 3 efficacy has proved elusive, and the company’s candid platform review reflects the scale of the setback. Life Science Daily News will continue to track these programmes as they develop, bringing you accurate, independent coverage from across the global life sciences pipeline.
